Literature DB >> 8713791

Proteins of the fibrinolytic system in human thrombi.

L A Robbie1, B Bennett, A M Croll, P A Brown, N A Booth.   

Abstract

The proteins of fibrinolysis have been quantified in human thrombi, to assess the balance between plasminogen activators and their major inhibitor PAI-1. The relative roles of PAI-1 and alpha 2-AP were also examined since we have previously shown that both platelet PAI-1 and plasma alpha 2-AP are important determinants of clot lysis in vitro. Extracts and sections were prepared from human thrombi for quantitative immunoassay and immunohistochemical staining respectively. PAI-1 and alpha 2-AP were present at high concentrations. Levels of t-PA and t-PA-PAI-1 complex were relatively low. Staining confirmed the presence of abundant PAI-1, associated primarily with platelet material within the thrombus and also with fibrin. Staining for alpha 2-AP was also intense and demonstrated strong association with fibrin. The alpha 2-AP concentration was similar to its high plasma concentration, whereas PAI-1 levels were up to 30 times greater than that in circulating blood, suggesting that active recruitment of platelets contributes to the high PAI-1 concentration in thrombi.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8713791

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  19 in total

1.  Combination treatment with rt-PA is more effective than rt-PA alone in an in vitro human clot model.

Authors:  Jason M Meunier; Christy K Holland; Tyrone M Porter; Christopher J Lindsell; George J Shaw
Journal:  Curr Neurovasc Res       Date:  2011-11       Impact factor: 1.990

Review 2.  Staphylococcal adaptation to diverse physiologic niches: an overview of transcriptomic and phenotypic changes in different biological environments.

Authors:  Sana S Dastgheyb; Michael Otto
Journal:  Future Microbiol       Date:  2015-11-19       Impact factor: 3.165

Review 3.  The neurovascular unit and combination treatment strategies for stroke.

Authors:  Li Zhang; Zheng Gang Zhang; Michael Chopp
Journal:  Trends Pharmacol Sci       Date:  2012-05-16       Impact factor: 14.819

4.  Hyperfibrinolysis.

Authors:  B J Hunt; H Segal
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

5.  Lytic resistance of fibrin containing red blood cells.

Authors:  Nikolett Wohner; Péter Sótonyi; Raymund Machovich; László Szabó; Kiril Tenekedjiev; Marta M C G Silva; Colin Longstaff; Krasimir Kolev
Journal:  Arterioscler Thromb Vasc Biol       Date:  2011-07-07       Impact factor: 8.311

Review 6.  Enhanced spontaneous thrombolysis: a new therapeutic challenge.

Authors:  I B Kovacs; D A Gorog; J Yamamoto
Journal:  J Thromb Thrombolysis       Date:  2006-06       Impact factor: 2.300

7.  Comparison of plasmin with recombinant tissue-type plasminogen activator in lysis of cerebral thromboemboli retrieved from patients with acute ischemic stroke.

Authors:  Victor J Marder; Ales Blinc; Theresa Gruber; Gregor Tratar; Miso Sabovic; Sidney Starkman; Reza Jahan; Gary Duckwiler; Fernando Vinuela; Satoshi Tateshima; David Liebeskind; Bruce Ovbiagele; Letisha Ali; Doojin Kim; Nestor Gonzalez; Paul M Vespa; Jeffrey L Saver
Journal:  Stroke       Date:  2011-06-23       Impact factor: 7.914

8.  Making the right choice: optimizing rt-PA and eptifibatide lysis, an in vitro study.

Authors:  George J Shaw; Jason M Meunier; Christopher J Lindsell; Arthur M Pancioli; Christy K Holland
Journal:  Thromb Res       Date:  2010-09-01       Impact factor: 3.944

9.  Assessment of coronary heart disease risk by combined analysis of coagulation factors.

Authors:  Nena Aleksic; Yao-Wei W Wang; Chul Ahn; Harinder S Juneja; Aaron R Folsom; Kenneth K Wu
Journal:  Atherosclerosis       Date:  2008-03-14       Impact factor: 5.162

10.  Individual lytic efficacy of recombinant tissue plasminogen activator in an in vitro human clot model: rate of "nonresponse".

Authors:  Jason M Meunier; Evan Wenker; Christopher J Lindsell; George J Shaw
Journal:  Acad Emerg Med       Date:  2013-05       Impact factor: 3.451

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.